The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Open accessAbstract
Purpose: To evaluate if diastolic blood pressure (dBP) ≥90 mm Hg during axitinib treatment is a marker of efficacy. Experimental Design: The relationship between dBP ≥90 mm Hg and efficacy was retrospectively explored across 5 phase II studies of single-agent axitinib for the treatment of 4 different tumor types. All patients had baseline BP ≤140/90 mm Hg and were stratified into 2 groups based on in-clinic BP measurements after initiating therapy: those with dBP <90 mm Hg throughout therapy and those with at least 1 dBP ≥90 mm Hg. Median overall survival (mOS), median progression-free survival (mPFS), objective response rate (ORR), and adverse events were evaluated by dBP group in individual and pooled analyses. Results: Two-hundred thirty patients were evaluated. Patients with dBP ≥90 mm Hg had a significantly lower relative risk of death than those with dBP <90 mm Hg [adjusted HR (95% CI) = 0.55 (0.39, 0.77); P < 0.001]. The relative risk of progression was also lower in patients with dBP ≥90 mm Hg [HR (95% CI) = 0.76 (0.54, 1.06), P = 0.107], and ORR was significantly higher (43.9% vs. 12.0%; P < 0.001). In an 8-week landmark analysis, mOS (25.8 vs. 14.9 months) and mPFS (10.2 vs. 7.1 months) were greater for patients in the ≥90 mm Hg group. Adverse events were similar between groups. Conclusions: Axitinib efficacy correlated with dBP ≥90 mm Hg. Further investigation of dBP as a predictive biomarker of efficacy in patients receiving axitinib is warranted. Clin Cancer Res; 17(11); 3841–9. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Cited by
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Self-citationSmall molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
Self-citationMcTigue, M., Murray, B. W., Chen, J. H., Deng, Y.-L., Solowiej, J., & Kania, R. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207759109 · Cited by 592
Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C., Vaishampayan, U., George, S., Olencki, T. E., Tarazi, J. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 370
Self-citation
Metadata
- Authors
- Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J. C., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., Kim, S., & Rixe, O.
- Venue
- Clinical Cancer Research
- Published
- 2011-06-01
- Volume
- 17
- Issue
- 11
- Pages
- 3841-3849
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2146950212
- Cited by
- 181
- References
- 1
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2806
- The paper
- Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J. C., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., Kim, S., & Rixe, O. (2011). Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2806
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.